Biotech / Medical
Spectral Medical Inc.
An SI Board Since October 2011
Posts SubjectMarks Bans Symbol
305 8 0 EDTXF
Emcee:  Sultan Type:  Unmoderated
Spectral is a Phase III company seeking U.S. FDA approval for its lead theranostics product for the treatment for severe sepsis and septic shock. Toraymyxin is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream. Directed by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis. Spectral's EUPHRATES trial is the world's first theranostics trial in the area of sepsis.

Toraymyxin has been approved for therapeutic use in Japan and Europe , and has been used safely and effectively in more than 80,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for Toraymyxin, and in November 2010, signed an exclusive distribution agreement for this product in Canada . More than 250,000 patients are diagnosed with severe sepsis and septic shock in North America each year, representing a greater than $1 billion market opportunity for Spectral. Spectral is listed on the Toronto Stock Exchange under the symbol SDI.

For further information please visit
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
305 Active licence listing health-products.canada.caSultan-last Thursday
304Spectral Announces Health Canada Approval of Its Proprietary Stand-Alone Pump foSultan1last Thursday
303We are on the final stretch of the long marathon for Spectral and the share holdSultan-February 9
302Effects of polymyxin B hemoperfusion on hemodynamics and prognosis in septic shoSultan-February 9
301 [graphic] TORONTO, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Spectral Medical Inc., (villiago-February 1
300Spectral Medical Announces the Appointment of Chief Financial Officer TORONTO,Sultan-February 1
299Sepsis: the Achilles’ heel of health care statnews.comSultan-January 30
298This woman survived life-threatening sepsis, but what came next was even worse Sultan-January 30
297Sepsis costs Medicare $6 billion in 2015, more than any other discharge modernSultan-January 26
296Events are starting to unfold which should amount to a good payday for us eventuvilliago-12/22/2017
295CardioBrief: FDA's Gottlieb Preparing To Lower The Bar To Approval ShiftingSultan-12/21/2017
294Inpatient High-Risk Antibiotic Use Increases Subsequent Risk of Sepsis infectioSultan-12/21/2017
293This has nothing to do with Spectral as such but because of Spectral's PhaseSultan-12/18/2017
292FDA Grants 510(k) Clearance for Spectral's Proprietary Stand-Alone Pump TOSultan212/18/2017
291Spectral to Launch Toraymyxin(TM)/EAA(TM) in Canada in Q1 2018 TORONTO, ONTARISultan-12/13/2017
289One reason from a knowledgeable, respected source: Message 31127355The Ox-11/28/2017 How can this not be a $2 to $3 stock?villiago-11/28/2017
287America Has a $27 Billion Sepsis Crisis bloomberg.comSultan211/27/2017
286Spectral Announces Third Quarter Results
285 35th International Vicenza Course on AKI & CRRT youtube.comSultan-11/14/2017
284Spectral Provides Update on FDA Meeting Regarding Its PMA Submission for ToraymySultan110/31/2017
283Critical Care Canada Forum (CCCF) Toronto Plenary Session Presentation: Sultan110/15/2017
282Sepsis & septic shock market to be worth $5.9 billion by 2026 linkedin.comSultan110/15/2017
281Spectral Presents Key EUPHRATES Trial Data at the Canadian Critical Care Forum Sultan110/4/2017
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2018 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.